MedPath

Preliminary Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low-weight Infants

Not Applicable
Terminated
Conditions
Patent Ductus Arteriosus
Registration Number
NCT03982342
Lead Sponsor
Nationwide Children's Hospital
Brief Summary

This is a pilot study to collect preliminary data for a larger, multicenter clinical trial proposal. The study will examine two strategies commonly used to treat preterm infants diagnosed with a patent ductus arteriosus (PDA). The PDA closes after birth for most term infants, but in many preterm infants, it remains open (patent). A PDA may present a complication for a number of short-term problems faced by preterm infants. Longer-term issues include the development of pulmonary hypertension and changes in the size and performance of the heart. There is ongoing debate as to whether or not the PDA requires intervention.

Detailed Description

Preterm infants diagnosed with a hemodynamically-significant patent ductus arteriosus (HSPDA) will be included. Specific criteria will be followed to determine if a patent ductus arteriosus (PDA) is "hemodynamically significant". Infants will be randomized to two different approaches for management of the PDA. The first will be catheter-based closure (intervention) and the second will be conservative management (non-intervention). Both procedures are standard practice at many institutions, including Nationwide Children's Hospital. Infants randomized to receive intervention will undergo a procedure in which a catheter is used to place an FDA-approved device within the PDA, to close it (like a plug). Infants randomized to the conservative management (non-intervention) group will be permitted time to see if the PDA closes on its own, naturally. However, if the PDA remains open and intervention is deemed medically necessary, they will also undergo the catheter closure procedure.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
1
Inclusion Criteria
  • Preterm infants ≤28 weeks gestational age with hemodynamically-significant patent ductus arteriosus (PDA) at 2 - 4 weeks of age.
  • Body weight greater than or equal to 700 grams
Exclusion Criteria
  • Significant genetic (ex.- Trisomy) or physiological (ex. - Omphalocele) abnormalities
  • Other cardiac disease NOT INCLUDING atrial-septal defects or ventricular septal defects (ex. Tetrology of Fallot, Single ventricle physiology)
  • Body weight less than 700 grams

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Time on Ventilatory Support RequiredWeekly for 1 month pre-closure (intervention group) or corresponding time point (non-intervention group); Weekly for 1 month post-closure (intervention group) or corresponding time point (non-intervention group); 36 weeks corrected gestational age

Period the participant is in need of ventilator support \[Synchronized Intermittent Mandatory Ventilation (SIMV), High Frequency Oscillatory Ventilation (HFOV), or similar\]

Supplemental Oxygen NeedPost-randomization (up to 6 weeks) for participants in both groups.

Weekly supplemental oxygen support required (in % fraction of inspired oxygen, FiO2)

Secondary Outcome Measures
NameTimeMethod
Number of Subjects Requiring Catheter-based Closure Due to Failed Conservative Management (Applies to Conservative Management Group Only)6 weeks post-randomization (to conservative management group)

How often (incidence) infants assigned to conservative management require intervention; failure of treatment method

Trial Locations

Locations (2)

Nationwide Children's Hospital

🇺🇸

Columbus, Ohio, United States

University of Tennessee Health Science Center

🇺🇸

Memphis, Tennessee, United States

Nationwide Children's Hospital
🇺🇸Columbus, Ohio, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.